METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New 'Tumor-Seeking' radiation therapy enters human trials for prostate cancer
Disease control OngoingThis clinical trial is testing a new targeted radiation treatment called [Ac-225]-PSMA-62 for men with advanced prostate cancer that has spread. The treatment uses a radioactive drug designed to find and deliver radiation directly to prostate cancer cells throughout the body. The…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 01, 2026 21:41 UTC
-
New hope for men battling aggressive prostate cancer
Disease control OngoingThis study is testing whether a drug called enfortumab vedotin, given alone or with other cancer drugs, can help control advanced prostate cancer that has spread and no longer responds to standard hormone therapies. It is for men whose cancer has progressed despite prior treatmen…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug duo aims to stall advanced prostate cancer
Disease control OngoingThis large, late-stage study tested whether adding a drug called olaparib to the standard treatment (abiraterone) is better at controlling advanced prostate cancer that has stopped responding to hormone therapy. It involved nearly 900 men worldwide who had not yet tried other tre…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Radioactive 'Tumor-Seeking' therapy battles advanced prostate cancer in major trial
Disease control OngoingThis study is testing whether a new radioactive drug that targets prostate cancer cells (called [Lu-177]-PNT2002) works better than standard hormone drugs for men with advanced prostate cancer that has spread and is no longer controlled by standard treatments. About 455 men whose…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New Two-Pronged attack on Tough-to-Treat prostate cancer
Disease control OngoingThis study is testing a new combination treatment for men with an advanced form of prostate cancer that has spread and no longer responds to standard hormone therapy. It combines a radioactive drug that seeks out cancer cells with a pill that blocks cancer's ability to repair its…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New combo attack on advanced prostate cancer
Disease control OngoingThis early-stage study is testing the safety of combining two drugs, nivolumab and Radium-223, for men with advanced prostate cancer that has spread to the bones and is no longer responding to standard hormone therapy. The goal is to see if this combination is safe and shows earl…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Targeted radiation zaps advanced prostate cancer in new trial
Disease control ENROLLING_BY_INVITATIONThis study is testing a new, personalized radiation treatment for men with advanced prostate cancer that has spread and is no longer responding to standard hormone-blocking drugs. The treatment uses a radioactive drug that seeks out and delivers radiation directly to prostate can…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New combo therapy fights spreading prostate cancer
Disease control OngoingThis large, late-stage study is testing whether adding a drug called olaparib to standard therapy (abiraterone) works better for men with advanced prostate cancer that has spread and is no longer controlled by hormone therapy alone. The goal is to see if the combination can delay…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug combo aims to tame aggressive prostate cancer
Disease control OngoingThis study is testing whether two drugs, abemaciclib and atezolizumab, can help control advanced prostate cancer that has spread and no longer responds to standard hormone treatments. The trial is enrolling men to receive one drug, the other, or both together, to see which approa…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New Two-Pronged attack tested for tough prostate cancer
Disease control OngoingThis study is testing whether adding a new immunotherapy drug called ONC-392 to an existing prostate cancer radiation treatment (Pluvicto) is safe and more effective. It is for men whose advanced prostate cancer has worsened despite prior hormone-blocking drugs and chemotherapy. …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
Targeted radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis study is testing a new targeted radiation treatment called FPI-2265 for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The treatment delivers radiation directly to cancer cells using a molecule that seeks out a protein o…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Radioactive 'Smart Bomb' targets advanced prostate cancer in first human trial
Disease control OngoingThis early-stage study is testing a new radioactive drug called 225Ac-pelgi in men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug is designed to seek out and deliver radiation directly to cancer cells while sparing healthy ti…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Scientists test drug combo for Tough-to-Treat prostate cancer
Disease control OngoingThis early-stage study is checking how two prostate cancer drugs, JNJ-56021927 and abiraterone acetate, interact in the body when taken together. It involves 57 men whose prostate cancer has spread and is no longer responding to standard hormone-blocking treatments. The main goal…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
New hope drug tested for Tough-to-Treat prostate cancer
Disease control OngoingThis is an early-stage study to check the safety and how the body processes a new drug called MK-5684 (opevesostat) in Japanese men with advanced prostate cancer. The cancer has spread and no longer responds to standard hormone therapy or chemotherapy. The main goal is to see wha…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
New hope for veterans with Tough-to-Treat prostate cancer
Disease control OngoingThis study is testing whether an immunotherapy drug called pembrolizumab can help control advanced prostate cancer that has stopped responding to standard hormone treatments. It is specifically for veterans whose cancer has one of two rare genetic features. The goal is to see if …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Mar 09, 2026 14:22 UTC
-
New scan seeks to spot deadliest prostate cancer
Diagnosis OngoingThis early-stage study is testing a new imaging agent for PET scans in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if this new tracer can better detect and locate cancer tumors by targeting a specific protein (CD…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Robert Flavell, MD, PhD • Aim: Diagnosis
Last updated Mar 03, 2026 14:06 UTC